20201109 Transgene BioInvent_SITC BT001_EN
Category: BT-001 (EN)
BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation
Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201015 – BT-001_SITC poster EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster here Poster Presentation
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
20200622b – BT-001_AACR poster EN
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a – Transgene PR AACR 3 posters
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001Marchand, Semmrich, Fend et al.Immuno-Oncology summitDownload the poster herePoster Presentation
